Cargando…
Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment
INTRODUCTION: MicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of ti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827834/ https://www.ncbi.nlm.nih.gov/pubmed/27064979 http://dx.doi.org/10.1371/journal.pone.0152032 |
_version_ | 1782426519561306112 |
---|---|
author | Al-Khanbashi, Manal Caramuta, Stefano Alajmi, Adil M. Al-Haddabi, Ibrahim Al-Riyami, Marwa Lui, Weng-Onn Al-Moundhri, Mansour S. |
author_facet | Al-Khanbashi, Manal Caramuta, Stefano Alajmi, Adil M. Al-Haddabi, Ibrahim Al-Riyami, Marwa Lui, Weng-Onn Al-Moundhri, Mansour S. |
author_sort | Al-Khanbashi, Manal |
collection | PubMed |
description | INTRODUCTION: MicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes. METHODS: Tissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, and Spearman, Wilcoxon signed-ranks tests. P≤0.05 was considered statistically significant. RESULTS: We analyzed 72 tissue samples and 108 serum samples from 9 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. This is one of the early reports on miR-3200 in response to treatment in breast cancer, as serum levels of miR-3200 found to decline during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates at time of diagnosis. CONCLUSION: Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. |
format | Online Article Text |
id | pubmed-4827834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48278342016-04-22 Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment Al-Khanbashi, Manal Caramuta, Stefano Alajmi, Adil M. Al-Haddabi, Ibrahim Al-Riyami, Marwa Lui, Weng-Onn Al-Moundhri, Mansour S. PLoS One Research Article INTRODUCTION: MicroRNAs (miRNAs) are small non-coding RNA that plays a vital role in cancer progression. Neo-adjuvant chemotherapy (NAC) has become the standard of care for locally advanced breast cancer. The aim of this study was to evaluate miRNA alterations during NAC using multiple samples of tissue and serum to correlate miRNA expression with clinico-pathological features and patient outcomes. METHODS: Tissue and serum samples were collected from patients with locally advanced breast cancer undergoing NAC at four time points: time of diagnosis, after the first and fourth cycle of doxorubicin/cyclophosphamide treatment, and after the fourth cycle of docetaxel administration. First, we evaluated the miRNA expression profiles in tissue and correlated expression with clinico-pathological features. Then, a panel of four miRNAs (miR-451, miR-3200, miR-21, and miR-205) in serum samples was further validated using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). The alterations in serum levels of miRNA, associations with clinical and pathological responses, correlation with clinico-pathological features, and survival outcomes were studied using Friedman, Mann-Whitney U, and Spearman, Wilcoxon signed-ranks tests. P≤0.05 was considered statistically significant. RESULTS: We analyzed 72 tissue samples and 108 serum samples from 9 patients and 27 patients, respectively. MicroRNA expression profiling of tumor versus normal tissue revealed more than 100 differentially expressed miRNAs. Serum miR-451 levels were significantly decreased during treatment, and higher serum levels were associated with improved clinical and pathological responses and disease-free survival. This is one of the early reports on miR-3200 in response to treatment in breast cancer, as serum levels of miR-3200 found to decline during NAC, and higher serum levels were associated with lower residual breast cancer burden and relapse rates at time of diagnosis. CONCLUSION: Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. Public Library of Science 2016-04-11 /pmc/articles/PMC4827834/ /pubmed/27064979 http://dx.doi.org/10.1371/journal.pone.0152032 Text en © 2016 Al-Khanbashi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Al-Khanbashi, Manal Caramuta, Stefano Alajmi, Adil M. Al-Haddabi, Ibrahim Al-Riyami, Marwa Lui, Weng-Onn Al-Moundhri, Mansour S. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title_full | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title_fullStr | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title_full_unstemmed | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title_short | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
title_sort | tissue and serum mirna profile in locally advanced breast cancer (labc) in response to neo-adjuvant chemotherapy (nac) treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827834/ https://www.ncbi.nlm.nih.gov/pubmed/27064979 http://dx.doi.org/10.1371/journal.pone.0152032 |
work_keys_str_mv | AT alkhanbashimanal tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT caramutastefano tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT alajmiadilm tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT alhaddabiibrahim tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT alriyamimarwa tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT luiwengonn tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment AT almoundhrimansours tissueandserummirnaprofileinlocallyadvancedbreastcancerlabcinresponsetoneoadjuvantchemotherapynactreatment |